Iqbal Mufti
Partner @ SR One
Basel, Switzerland
Iqbal Mufti is a Series A investor at SR One in Basel focused on Medical and Life Science. Iqbal Mufti
- Total investments:
- 3
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Iqbal Mufti invests in
Stages Iqbal Mufti invests in
Countries Iqbal Mufti invests in
Investment Focus
Industry
- Medical 1 (33%)
- Life Science 1 (33%)
- Biotechnology 1 (33%)
Stage
- Series A 1 (33%)
- Series B 1 (33%)
- Funding Round 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Windward Bio
|
Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field. | $165M / Series B / May 04, 2026 | |
|
Windward Bio
|
Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field. | $200M / Series A / Jan 10, 2025 | |
|
Windward Bio
|
Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field. |
Co-Investors
About SR One
SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care. Since 1985, SR One has invested approximately 800 million in more than 180 companies.
SR One Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Jill Carroll
Partner
|
|||
Simeon George
Chief Executive Officer
|
|||
Christopher Y. Chai
Venture Partner
|
|||
|
Iqbal Mufti
Partner
|
|||
Jens Eckstein
President
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Iqbal Mufti invest in?
Iqbal Mufti invests primarily in Medical, Life Science and Biotechnology startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Iqbal Mufti last invest?
The most recent investment recorded for Iqbal Mufti closed in May 2026. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
